Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115758

Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II).

K Nishio, Y Sugimoto, Y Fujiwara, T Ohmori, T Morikage, Y Takeda, M Ohata, and N Saijo

Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Nishio, K. in: JCI | PubMed | Google Scholar

Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Sugimoto, Y. in: JCI | PubMed | Google Scholar

Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Fujiwara, Y. in: JCI | PubMed | Google Scholar

Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Ohmori, T. in: JCI | PubMed | Google Scholar

Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Morikage, T. in: JCI | PubMed | Google Scholar

Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Takeda, Y. in: JCI | PubMed | Google Scholar

Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Ohata, M. in: JCI | PubMed | Google Scholar

Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Saijo, N. in: JCI | PubMed | Google Scholar

Published May 1, 1992 - More info

Published in Volume 89, Issue 5 on May 1, 1992
J Clin Invest. 1992;89(5):1622–1628. https://doi.org/10.1172/JCI115758.
© 1992 The American Society for Clinical Investigation
Published May 1, 1992 - Version history
View PDF
Abstract

We have investigated the effect of cis-diamminedichloroplatinum(II) (CDDP) on signal transduction pathways. CDDP treatment did not cause any change in the binding of [3H]-phorbol dibutyrate to PC-9 (human lung adenocarcinoma cell line) cells, a measure of protein kinase C activation. However, 2-h CDDP treatment (20 micrograms/ml) caused approximately 200% increase in 1,2-sn-diacylglycerol (DAG) production and approximately 50% decrease in inositol 1,4,5-triphosphate production. To explore the different source of DAG, we analyzed phospholipids labeled with [14C]choline by TLC and revealed that [14C]choline-labeled phosphatidylcholine (PC) was decreased to 50% by CDDP treatment. This suggested that PC turnover was increased by CDDP-treatment. PC-specific phospholipase C (PC-PLC) activity was increased to 2.5-fold (2.58 +/- 0.28 nmol/mg protein per min) by 2 h CDDP (20 micrograms/ml) treatment compared with control (1.05 +/- 0.24 nmol/mg protein per min). Treatment of CDDP also stimulated PC-PLC in the crude membrane extract from PC-9 cells. CDDP had no effect on the activities of phospholipase A2 and D. Trans-DDP, which has far less cytotoxicity than its stereoisomer, CDDP, did not cause any change in PC-PLC activity. A significant inhibition of DNA synthesis (less than 80%) occurred 4 h after 2 h CDDP (20 micrograms/ml) treatment. These results demonstrated that CDDP-induced PC-PLC activation was an early event in CDDP-induced cytotoxicity and suggested that the effects of CDDP on signal transduction pathways had an important role in CDDP-induced cytotoxicity.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1622
page 1622
icon of scanned page 1623
page 1623
icon of scanned page 1624
page 1624
icon of scanned page 1625
page 1625
icon of scanned page 1626
page 1626
icon of scanned page 1627
page 1627
icon of scanned page 1628
page 1628
Version history
  • Version 1 (May 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts